List of Daliresp drug patents

Daliresp is owned by Astrazeneca.

Daliresp contains Roflumilast.

Daliresp has a total of 5 drug patents out of which 0 drug patents have expired.

Daliresp was authorised for market use on 28 February, 2011.

Daliresp is available in tablet;oral dosage forms.

Daliresp can be used as treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations.

The generics of Daliresp are possible to be released after 08 March, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431154 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Feb, 2023

(13 days from now)

US9468598 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
Feb, 2023

(13 days from now)

US8536206 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(1 year, 1 month from now)

US8604064 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(1 year, 1 month from now)

US8618142 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(1 year, 1 month from now)

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 28 February, 2011

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

How can I launch a generic of DALIRESP before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in